Products for Research Use Only

Propacetamol

CAT: 0804-HY-145453-01Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145453-01Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Propacetamol is an orally active prodrug of Acetaminophen , which exerts antipyretic and analgesic effects after metabolism. Propacetamol reduces Aspirin (ASA) (HY-14654) -induced elevation of malondialdehyde (MDA) in gastric mucosa and plasma, regulates the levels of gastric mucosal glutathione (GSH and GSSG) to maintain cellular antioxidant defense, and increases gastric mucosal uric acid (UA) levels. Propacetamol exerts a dose-dependent protective effect against ASA-induced gastric mucosal damage in rats. Propacetamol can be used for the study of gastric mucosal injury by interfering with oxidative stress[1][2][3].
CAS Number
66532-85-2
UNSPSC
12352005
Target
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/propacetamol.html
Purity
98.02
Solubility
DMSO : 33.33 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(OC1=CC=C(NC(C)=O)C=C1)CN(CC)CC
Molecular Formula
C14H20N2O3
Molecular Weight
264.32
References & Citations
[1]Liou GG, et al. N-Acetyl Cysteine Overdose Inducing Hepatic Steatosis and Systemic Inflammation in Both Propacetamol-Induced Hepatotoxic and Normal Mice. Antioxidants (Basel) . 2021 Mar 12;10 (3) :442.|[2]Zhang Y, et al. Enhanced analgesic effects of propacetamol and tramadol combination in rats and mice. Biol Pharm Bull. 2011;34 (3) :349-53. doi: 10.1248/bpb.34.349|[3]Galunska B, et al. Effects of paracetamol and propacetamol on gastric mucosal damage and gastric lipid peroxidation caused by acetylsalicylic acid (ASA) in rats. Pharmacol Res. 2002 Aug;46 (2) :141-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2